(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 May 2009 (07.05.2009)

PCT

(10) International Publication Number
WO 2009/058797 A1

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/US2008/081493

(22) International Filing Date: 29 October 2008 (29.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/984,910 2 November 2007 (02.11.2007) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CAI, Yuping, Anthony** [CN/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **GATELY, Dennis, Patrick** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **HE, Luhong** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **LEUNG, Donmienne, Doen** [AU/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **LUAN, Peng** [CN/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **SWANSON, Barbara, Anne** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **TANG, Ying** [CN/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **WITCHER, Derrick, Ryan** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(74) Agents: **SHARP, Robert, L.** et al.; Eli Lilly and Company, Patent Division, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) Title: ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF

(57) Abstract: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.

WO 2009/058797 A1